Phase 2 study of PVX108 to commence in United States and Australia Dr Robert A. Wood, professor of pediatrics at the Johns Hopkins...

27 August 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...

13 July 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for peanut...

01 November, 2020, Melbourne, Victoria - Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...

30 September 2019, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for...

June 4, 2019, Melbourne, Victoria –Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and...